Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57892) - R3 - Effective February 24, 2022

This Billing and Coding Article has been revised and published for notice under contract numbers: 02101 (AK), 02201 (ID), 02301 (OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), and 03601 (WY).

Effective Date: February 24, 2022

Summary of Article Changes: Under ICD-10 codes that support medical necessity Group I: Codes added C92.90, C92.91, C92.92, C93.90, C93.92, D46.4, D46.9, D61.9, D64.9, and D69.6. The deletion of these codes in Revision 1 was done in error and is retroactive effective for dates of service on or after 7/8/2021.

Visit the Molecular Diagnostic Services (MolDX) webpage to access the locally hosted MolDX Medicare Coverage Article from the “Covered Tests” or the “Excluded Tests” webpage.

To view the complete listing of locally hosted coverage articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Medicare Coverage Articles webpage.

Last Updated Apr 28 , 2022